中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 767-772

Clinical diagnosis， treatment， and prognosis of gallbladder sarcomatoid carcinoma： An analysis of 16 cases

DOI: 10.12449/JCH240420
  • a.

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China

  • b.

    Department of Pathology，The First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China

Research funding:

Key Project of Henan Provincial Medical Science and Technology Research Plan (SBGJ202002068)

More Information
  • Corresponding author: LU Taiying， fccluty@zzu.edu.cn （ORCID： 0000-0001-5690-8526）
  • Received Date: 2023-07-19
  • Accepted Date: 2023-07-27
  • Published Date: 2024-04-25
    Abstract
  •   Objective  To investigate the clinicopathological features， diagnosis and treatment methods， and prognosis of gallbladder sarcomatoid carcinoma （GBSC）.  Methods  A retrospective analysis was performed for the clinical data of 16 patients with GBSC who were admitted to The First Affiliated Hospital of Zhengzhou University from January 2015 to April 2023， including general information， clinical manifestations， imaging features， pathological features， and treatment modality， and follow-up was performed for all patients. The Kaplan-Meier method was used to perform the survival analysis and plot the survival curve， and the Log-rank test was used for comparison between groups.  Results  Among the 16 patients， there were 6 male patients and 10 female patients， with a mean age of 62.9±8.4 years. The main clinical manifestations were right upper abdominal pain in 13 patients （81.3%）， nausea in 5 patients （31.3%）， abdominal distension in 4 patients （25.0%）， poor appetite in 3 patients （18.8%）， weakness in 2 patients （12.5%）， fever in 2 patients （12.5%）， and jaundice in 1 patient （6.3%）， and 3 patients were asymptomatic and were found to have this disease by physical examination. Of all patients， 81.3% （13/16） were in the advanced stage （stage Ⅲ/Ⅳ） at the time of initial diagnosis. Histopathological examination showed that some cancer cells were spindle-shaped under the microscope， with marked nuclear division and noticeable heteromorphism. Immunohistochemistry showed a positive expression rate of 100% （16/16） for Vimentin， AE1/AE3， and CK8/18， and Ki-67 proliferation index was highly expressed in 81.3% （13/16） of the patients （≥50%）， with a median of 70% （range 20%‍ ‍—‍ ‍90%）. All 16 patients underwent surgical treatment， with radical surgery in 11 patients and palliative surgery in 5 patients， among whom 9 received R0 resection， 2 received R1 resection， and 5 received R2 resection， and 7 patients received adjuvant therapy after surgery. Effective follow-up was achieved for all 16 patients， with a follow-up time of 0.5‍ ‍—‍ ‍26.0 months and a median follow-up time of 11.0 months. By the end of follow-up， 2 patients survived and 14 patients died due to tumor recurrence or metastasis， with a median survival time of 10.0 months， and the 1- and 2-year cumulative survival rates after surgery were 31.3% and 8.3%， respectively. The prognostic analysis showed that TNM stage （χ2=6.727， P=0.009）， surgical approach （χ2=7.508， P=0.006）， margin condition （χ2=7.934， P=0.005）， and adjuvant therapy （χ2=4.608， P=0.032） were associated with the prognosis of patients.  Conclusion  The clinical manifestations of GBSC lack specificity， and a confirmed diagnosis relies on immunohistochemical analysis. Most patients are in the advanced disease at the time of initial diagnosis and tend to have a poor prognosis. There are currently no targeted therapies for this disease， and radical surgery with negative margins and adjuvant therapy can improve the survival rate of patients.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    LIMAIEM F, BAYAR R, OMRANI S. Sarcomatoid carcinoma of the gallbladder: A rare and aggressive form of gallbladder cancer[J]. Clin Case Rep, 2023, 11( 1): e6876. DOI: 10.1002/ccr3.6876.
    [2]
    ZOU RQ, HU HJ, LV TR, et al. Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma of the gallbladder[J]. Front Oncol, 2022, 12: 1009673. DOI: 10.3389/fonc.2022.1009673.
    [3]
    LIU KH, YEH TS, HWANG TL, et al. Surgical management of gallbladder sarcomatoid carcinoma[J]. World J Gastroenterol, 2009, 15( 15): 1876- 1879. DOI: 10.3748/wjg.15.1876.
    [4]
    RAHMAN R, SIMOES EJ, SCHMALTZ C, et al. Trend analysis and survival of primary gallbladder cancer in the United States: A 1973-2009 population-based study[J]. Cancer Med, 2017, 6( 4): 874- 880. DOI: 10.1002/cam4.1044.
    [5]
    GOTZMANN J, MIKULA M, EGER A, et al. Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis[J]. Mutat Res, 2004, 566( 1): 9- 20. DOI: 10.1016/s1383-5742(03)00033-4.
    [6]
    FU YT, CHENG AL. Vimentin induced EMT the movers in tumor invasion and metastasis[J]. Med Sci J Cent South China, 2019, 47( 1): 89- 91, 94. DOI: 10.15972/j.cnki.43-1509/r.2019.01.024.

    付祎婷, 程爱兰. 波形蛋白诱导EMT在肿瘤侵袭转移中的研究进展[J]. 中南医学科学杂志, 2019, 47( 1): 89- 91, 94. DOI: 10.15972/j.cnki.43-1509/r.2019.01.024.
    [7]
    HOU JN, XING LH, YUAN YF. A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung[J]. Clin Exp Med, 2018, 18( 4): 555- 562. DOI: 10.1007/s10238-018-0517-2.
    [8]
    WANG QB, CUI BK, WENG JM, et al. Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver[J]. J Gastrointest Surg, 2012, 16( 9): 1715- 1726. DOI: 10.1007/s11605-012-1946-y.
    [9]
    DING L, BI ZF, YUAN H, et al. Sarcomatoid carcinoma in the head and neck: A population-based analysis of outcome and survival[J]. Laryngoscope, 2021, 131( 2): E489- E499. DOI: 10.1002/lary.28956.
    [10]
    CHENG JY, WANG CH, CHEN JH, et al. Sarcomatoid carcinomas of the liver,gallbladder,and pancreas: A clinicopathological portrait and literature review[J]. J Clin Hepatol, 2020, 36( 10): 2270- 2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.

    程捷瑶, 王沧海, 陈建宏, 等. 肝胆胰肉瘤样癌的临床病理特征及文献复习[J]. 临床肝胆病杂志, 2020, 36( 10): 2270- 2273. DOI: 10.3969/j.issn.1001-5256.2020.10.022.
    [11]
    RAN SH, CHEN FX, ZHANG YH, et al. The imaging findings of sarcomatoid carcinoma of gallbladder: 6 cases report[J]. Chin J Hepatobiliary Surg, 2023, 29( 5): 370- 372. DOI: 10.3760/cma.j.cn113884-20221230-00485.

    冉淑华, 陈凤喜, 张雨涵, 等. 胆囊肉瘤样癌6例影像学表现分析[J]. 中华肝胆外科杂志, 2023, 29( 5): 370- 372. DOI: 10.3760/cma.j.cn113884-20221230-00485.
    [12]
    KIM MJ, YU E, RO JY. Sarcomatoid carcinoma of the gallbladder with a rhabdoid tumor component[J]. Arch Pathol Lab Med, 2003, 127( 10): e406- e408. DOI: 10.5858/2003-127-e406-SCOTGW.
    [13]
    TASKIN OC, AKKAS G, MEMIS B, et al. Sarcomatoid carcinomas of the gallbladder: Clinicopathologic characteristics[J]. Virchows Arch, 2019, 475( 1): 59- 66. DOI: 10.1007/s00428-019-02583-z.
    [14]
    HU ZH, LI ZW, SHEN L, et al. Surgical therapy and prognosis of sarcomatoid carcinoma of the gallbladder[J]. Hepatobiliary Pancreat Dis Int, 2010, 9( 2): 175- 179.
    [15]
    OKABAYASHI T, SUN ZL, MONTGOMEY RA, et al. Surgical outcome of carcinosarcoma of the gall bladder: A review[J]. World J Gastroenterol, 2009, 15( 39): 4877- 4882. DOI: 10.3748/wjg.15.4877.
    [16]
    YUAN ZJ, SHUI YJ, LIU LH, et al. Postoperative recurrent patterns of gallbladder cancer: Possible implications for adjuvant therapy[J]. Radiat Oncol, 2022, 17( 1): 118. DOI: 10.1186/s13014-022-02091-6.
    [17]
    QIN Q, LIU M, WANG X. Gallbladder sarcomatoid carcinoma: Seven case reports[J]. World J Clin Cases, 2020, 8( 17): 3881- 3889. DOI: 10.12998/wjcc.v8.i17.3881.
    [18]
    BENSON AB, D’ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19( 5): 541- 565. DOI: 10.6004/jnccn.2021.0022.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (303) PDF downloads(44) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return